Fig. 2From: HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effectHIF-1α inhibitor echinomycin reduces acute GVHD in mice. Lethally irradiated Balb/c mice were infused with syngeneic or allogeneic bone marrow cells and splenic T cells from Balb/c (syn-HSCT) or C57BL/6(allo-HSCT) mice. Following HSCT, mice were treated with vehicle or echinomycin, and observed daily through day 70 post HSCT for survival (a). ***P < 0.001; allo-HSCT vehicle vs allo-HSCT echinomycin. GVHD scores were given weekly based on weight loss, posture, activity, fur texture, and skin integrity (b). Data in b are shown as mean ± SEM. *P < 0.05, **P < 0.01; allo-HSCT vehicle vs allo-HSCT echinomycin. Data are representatives of two independent experiments with n = 5 in syn-HSCT groups and n = 12 in allo-HSCT groupsBack to article page